TransPerfect Life Sciences announced that ARCA Biopharma has selected TransPerfect’s Trial Interactive eTMF solution as their enterprise platform for clinical trials.
ARCA Biopharma is a Colorado-based biopharmaceutical company that focuses on developing genetically targeted therapies for cardiovascular diseases. They initially selected TransPerfect’s Trial Interactive eTMF to support a Phase 2 trial conducted across 50 sites, and will be using the multitenant, cloud-based solution to move all trials to a paperless environment.
The Trial Interactive e-clinical platform was designed by clinical professionals, for clinical professionals. It is used by biopharmaceutical organizations and CROs to streamline product development lifecycles in a secure 21 CFR Part 11-compliant environment. Trial Interactive speeds time to market by moving cumbersome traditional paper-based study start-up and TMF management to the cloud. Stakeholders have real-time access to documentation and transparency into workflows, which drastically reduces travel and shipping requirements associated with review and reconciliation.
“ARCA Biopharma is doing incredible work in the cardiovascular space, and their innovative approach to development is truly ground-breaking,” said Michael Smyth, General Manager, Life Sciences Solutions at TransPerfect. “By moving to a cloud-based solution for TMF management, ARCA is able to optimize trial decisions around key elements like site selection and performance, study start-up, and management of critical study data.”